Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | Chief Scientific Officer | April 28, 2021 | May 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date April 28, 2021 · Filed May 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.92 · Expires 2031-04-29 | Direct | 9,000 |
Reported balance
After 2021-04-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-29 · Grant · Acquired 9,000 · Balance 9,000 F1: This option shall vest and become exercisable over a period of three years from the Grant Date, April 28, 2021, with 25% vesting on the Grant Date, and the remainder vesting in equal installments over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable over a period of three years from the Grant Date, April 28, 2021, with 25% vesting on the Grant Date, and the remainder vesting in equal installments over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2021 Filed May 3, 2021 20:02 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $11.92 | $0.00 |
DisclosureSEC source: 0001213900-21-024225 · ownership.xml · derivative · entry 1 Strapps Walter · CIK 0001849041 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of three years from the Grant Date, April 28, 2021, with 25% vesting on the Grant Date, and the remainder vesting in equal installments over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:37 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 99,133 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001213900-21-013236 · ownership.xml · derivative · entry 1 Strapps Walter · CIK 0001849041 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,133 Underlying: Common Stock · 99,133 shares Expires 2031-02-28 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, March 1, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| February 05, 2021 Filed Apr 7, 2021 20:08 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 79,094 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001213900-21-020627 · ownership.xml · derivative · entry 1 Strapps Walter · CIK 0001849041 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,094 Underlying: Common Stock · 79,094 shares Expires 2031-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.